

# CONTENT

Welcome message	6
E.K. Frey – E. Werle Foundation of the Henning L. Voigt Family & HENNER GRAEFF Foundation	7
Programme overview	9
List of invited speakers	10
Programme Wednesday 25 September 2019	11
Programme Thursday 26 September 2019	12
Programme Friday 27 September 2019	13
<b>SESSION 01 - KLK GENETICS AND BEYOND (GENETICS, GENOMICS, OTHER 'OMICS' TECHNOLOGIES)</b>	<b>15</b>
Scorilas: Identification of novel Kallikrein gene isoforms and their targeted non coding RNAs. A new area of novel tumor biomarkers	16
González: Epigenetic regulation of the Kallikrein family	17
Batra: A functional PSA prostate cancer susceptibility genetic variant confers both reduced and aggressive cancer risk	18
Koistinen: KLK transcript levels in prostate cancer	19
<b>SESSION 02 - KLKS IN MALIGNANT DISEASES (BIOMARKERS AND PATHOPHYSIOLOGY)</b>	<b>20</b>
Yousef: In silico navigation of kallikrein gene expression in different malignancies and their potential clinical utility	21
Krizova: Distinct KLK3 expression can aid pathologists in differential diagnosis of benign structures vs. prostatic carcinoma	22
Brattsand: KLK4 and Prostate Cancer	23
Ren: Individualizing ovarian cancer treatment with KLKs as novel personalized biomarkers of therapeutic response and relapse	24
Gong: Clinical relevance of kallikrein-related peptidase 5 and 7 mRNA expression levels in tumor tissue of advanced high-grade serous ovarian cancer patients (FIGO III/IV)	25
Dorn: High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients	26
<b>SESSION 03 - KLKS IN PHYSIOLOGY AND PATHOPHYSIOLOGY (PHYSIOLOGIC SYSTEMS AND DISEASES)</b>	<b>27</b>
Petrova: Spink5 conditional knock-out mice represent a viable model of Netherton syndrome allowing further understanding of skin and immune abnormalities	28
Hovnanian: Epidermis-specific Kallikrein 14 overexpression in transgenic mice leads to major hair shaft defects, desmoglein 3 and 4 degradation and skin inflammation	29
Courty: Differential roles of KLKs in influenza virus infection	30
Bonda: Role of the kallikrein-related peptidase 5 in the bronchial epithelial remodeling associated with chronic obstructive pulmonary disease and lung cancer	31
Yi: KLK5 in airway inflammation and epithelial barrier dysregulation	32
<b>SESSION 04 - KLKS IN TISSUE AND CELL SIGNALING</b>	<b>33</b>
Hollenberg: Proteinase-mediated signalling in the inflammatory tissue microenvironment: KLKs, proteinase-activated receptors (PARs) and more	34
Goldhardt: Kallikrein-related peptidase 6 in cerebrospinal fluid of patients with Alzheimer's disease is associated with CSF-TAU, FDG and AMYLOID-PET	35
Brix: Kallikreins and cysteine cathepsins act at opposite poles of thyroid epithelial cells	36
Williams: The role of mechanosensitive KLK10 in endothelial biology and atherosclerosis	37
Jeltsch: KLK3 activates VEGF-C and VEGF-D	37
<b>SESSION 05 - THERAPEUTIC POTENTIAL OF KLKS (&amp; DRUG DESIGN)</b>	<b>39</b>
Harris: Design and recombinant production of a bispecific inhibitor of KLK5 and KLK7	40
Paolo: Novel putative kallikrein-7 inhibiting compounds identified through a fluorescence-based enzyme kinetic screen of a targeted library	41
El Amri: Pharmacological modulators of kallikrein-related peptidases: Conception, characterisation and therapeutical applications in inflammation and neurodegeneration	42
<b>SESSION 06 - STRUCTURAL AND FUNCTIONAL ASPECTS OF KALLIKREINS, THEIR SUBSTRATES AND INHIBITORS</b>	<b>43</b>
Goettig: The dynamic structure of KLK8 in activity and inhibition	44
Lilja: Elucidating the effects of chymotrypsin-like and trypsin-like catalytic activity by prostate specific antigen and human kallikrein 2 on prostate tissue microenvironment, tumorigenesis and blood release	45
Papo: Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries	46
<b>SESSION 07 - KLKS IN PROTEOLYTIC (ACTIVATION) NETWORKS</b>	<b>47</b>
Kantyka: Processing of pro-MMPs by KLK14 – a new level of extracellular matrix proteolysis regulation	48
Käfinger: KLK4-mediated cleavage of CXCR3-ligands as an immune evasion mechanism in ovarian cancer	49

Zhang: Unlocking the KLK activome in drug-resistant cancer: imaging, biomarkers and target validation using novel activity probes	50
<b>SESSION 08 - HENNER GRAEFF FOUNDATION &amp; E.K. FREY - WERLE FOUNDATION SESSION</b>	<b>51</b>
Loessner: Kallikrein-related peptidases are key elements in the tumour microenvironment	52
Sananes: Combinatorial Engineering of APPI Variant with Improved Proteolytic Resistance and KLK6 Selectivity for Cancer Imaging and Therapy	53
Srinivasan: Prostate cancer risk associated Single Nucleotide Polymorphism affects PSA glycosylation and its function	54
<b>CLOSING</b>	
Diamandis: Kallikrein memoirs and future predictions	55
<b>POSTER SESSION</b>	<b>56</b>
(PO-1) Suomilide and human trypsin selective inhibition to prevent prostate cancer cell invasion	57
(PO-2) First-in-class inhibitors of kallikrein-related peptidase 6 promote oligodendrocyte differentiation	58
(PO-3) KLK4-mediated cleavage of CX3CL1/fractalkine	59
(PO-4) Generation of specific nanobodies targeting kallikrein-related peptidases in alpacas in Chile	60
(PO-5) Analyzing the proteolytic network interactions of tissue kallikreins and matrix metalloproteinases using CleavEx libraries	61
(PO-6) A novel role of a recombinant Kunitz-BPTI-like inhibitor towards KLK5 and KLK7	62
(PO-7) Novel CRISPR/Cas9 mouse models to study Klk proteolytic networks in vivo: systematic phenotypic screen	63
(PO-8) Impaired lactation in Klk5-/-Klk7-/- deficient female mice	64
(PO-9) Clinical relevance of cysteine-rich intestinal protein 1 (CRIP1) mRNA expression in advanced high-grade serous ovarian cancer	65
(PO-10) Tissue factor pathway inhibitor 2 regulates kallikrein-related peptidase 5 functions in lung diseases	66
(PO-11) Infection with Herpes Simplex Virus Type 1 alters the expression of KLK6 in vivo and in vitro	67
(PO-12) Selective dysregulation of the serine protease KLK14 in stable and exacerbated COPD	68
(PO-13) Gut Bacterial proteases: at the cutting edge of IBD	69
(PO-14) Diverse functions of KLK8, KLK13 and KLK14 in the regulation of the wound healing process	70
(PO-15) Identification and study of alternative 3'-untranslated regions (3'-UTRs) of kallikrein-related peptidase (KLK) gene family members using next-generation sequencing (NGS)	71
(PO-16) Exploring protein expression of members of KLK family in prostate cancer	72
(PO-17) Characterization of poloxamer based micelles as drug delivery agents for human tissue kallikrein 7 antibodies generated by phage display	73
List of participants	74
Notes	76